Meeting
2023 ASCO Genitourinary Cancers Symposium
Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
Authors
Can Aydogdu
Department of Urology, University Hospital, LMU Munich, Munich, Germany, Munich, Germany
Can Aydogdu , Florian Urban , Alexander Tamalunas , Elena Berg , Melanie Götz , Severin Rodler , Volker Heinemann , Christian Stief , Jozefina Casuscelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 185)
DOI
10.1200/JCO.2023.41.6_suppl.185
Abstract #
185
Poster Bd #
E20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).
First Author: Oscar Reig Torras
Poster
2023 ASCO Annual Meeting
Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.
First Author: Anis Hamid
Poster
2017 Genitourinary Cancers Symposium
Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.
First Author: Nedal Bukhari
Poster
2023 ASCO Annual Meeting
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Susan Halabi